Screener
Castle Biosciences CSTL EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Castle Biosciences’s reported figures.
Based on trailing twelve months.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
FAQ
- What is Castle Biosciences's EBITDA margin?
- Castle Biosciences (CSTL) reported EBITDA margin of -5.4% in Q1 2026.
- How has Castle Biosciences's EBITDA margin changed year-over-year?
- Castle Biosciences's EBITDA margin decreased by 165.4% year-over-year, from 8.2% to -5.4%.
- What is the long-term trend for Castle Biosciences's EBITDA margin?
- Over 5 years (2020 to 2025), Castle Biosciences's EBITDA margin has grown at a -42.8% compound annual growth rate (CAGR), from -9.7% to -0.6%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Castle Biosciences's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude